{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/65736d39d32e730012c98919/6a598ab67a878a3380370304?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Parkinson’s in the Clinic, Insilico enters Phase III, Vertex Acquires Crinetics ","description":"<p>Promise hits Parkinson’s disease therapy, as a Phase I/II clinical study has demonstrated the feasibility of transplanting stem-cell-derived dopamine progenitor cells into the brain. In preclinical research, a new platform uses the brain’s fluid transport pathways to effectively deliver AAVs to therapeutic targets in mice. We’ll also cover the accelerating infrastructure moment for AI-driven drug discovery, with billion-dollar investments flowing into end-to-end platforms driven by models and compute, rather than single drug assets. In business, Insilico’s revenue leaps as the company’s AI-developed lead candidate moves to Phase III, while Vertex acquires Crinetics for $10 billion.&nbsp;&nbsp;</p><p><br></p><p>&nbsp;</p><p>Join <em>GEN</em> editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news. &nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Listed below are links to the <em>GEN</em> stories referenced in this episode of <em>Touching Base</em>: &nbsp;</p><p>&nbsp;</p><p><a href=\"https://www.genengnews.com/topics/omics/engineered-aavs-harness-glymphatic-system-to-reach-brain-targets-in-mice/\" rel=\"noopener noreferrer\" target=\"_blank\">Engineered AAVs Harness Glymphatic System to Reach Brain Targets in Mice</a>&nbsp;</p><p><em>GEN</em>, July 9, 2026&nbsp;</p><p>&nbsp;</p><p><a href=\"https://www.genengnews.com/topics/drug-discovery/stem-cell-therapy-shows-promise-in-first-human-parkinsons-disease-trial/\" rel=\"noopener noreferrer\" target=\"_blank\">Stem Cell Therapy Shows Promise in First Human Parkinson’s Disease Trial</a>&nbsp;</p><p><em>GEN</em>, July 9, 2026&nbsp;</p><p>&nbsp;</p><p><a href=\"https://www.genengnews.com/topics/artificial-intelligence/pharma-races-to-scale-ai-as-billions-flow-into-drug-discovery/\" rel=\"noopener noreferrer\" target=\"_blank\">Pharma Races to Scale AI as Billions Flow into Drug Discovery</a>&nbsp;</p><p>By Fay Lin, PhD, <em>GEN Edge</em>, July 6, 2026&nbsp;</p><p>&nbsp;</p><p><a href=\"https://www.genengnews.com/topics/artificial-intelligence/stockwatch-insilico-projects-profit-revenue-leaps-as-ai-developed-lead-candidate-moves-to-phase-iii/\" rel=\"noopener noreferrer\" target=\"_blank\">StockWatch: Insilico Projects Profit, Revenue Leaps as AI-Developed Lead Candidate Moves to Phase III</a>&nbsp;</p><p>By Alex Philippidis, <em>GEN Edge</em>, July 12, 2026&nbsp;</p><p>&nbsp;</p><p><a href=\"https://www.genengnews.com/topics/translational-medicine/vertex-eyes-expansion-beyond-cystic-fibrosis-with-planned-10b-crinetics-buyout/\" rel=\"noopener noreferrer\" target=\"_blank\">Vertex Eyes Expansion Beyond Cystic Fibrosis with Planned $10B Crinetics Buyout</a>&nbsp;</p><p>By Alex Philippidis, <em>GEN Edge</em>, July 7, 2026&nbsp;</p><p>&nbsp;</p><p><a href=\"https://www.genengnews.com/topics/drug-discovery/top-20-drugs-heading-for-the-patent-cliff-2026-2029/\" rel=\"noopener noreferrer\" target=\"_blank\">Top 20 Drugs Heading for the Patent Cliff, 2026-2029</a>&nbsp;</p><p>By Alex Philippidis, <em>GEN Magazine</em>, Nov 1, 2025&nbsp;</p><p>&nbsp;</p><p><a href=\"https://www.genengnews.com/category/multimedia/podcasts/touching-base/\" rel=\"noopener noreferrer\" target=\"_blank\">Touching Base Podcast</a> &nbsp;</p><p>Hosted by Corinna Singleman, PhD &nbsp;</p><p>&nbsp;</p><p><a href=\"https://www.insideprecisionmedicine.com/category/multimedia/podcasts/\" rel=\"noopener noreferrer\" target=\"_blank\">Behind the Breakthroughs</a> &nbsp;</p><p>Hosted by Jonathan D. Grinstein, PhD &nbsp;</p><p>&nbsp;</p><p><a href=\"https://www.genengnews.com/resources/the-state-of-biologics-testing-2026/\" rel=\"noopener noreferrer\" target=\"_blank\">The State of Biologics Testing 2026</a>&nbsp;</p><p>Charles River Laboratories and <em>GEN</em>, June 10, 2026&nbsp;</p>","author_name":"Genetic Engineering & Biotechnology News (GEN)"}